Financial Architects, Inc Alnylam Pharmaceuticals, Inc. Transaction History

Financial Architects, Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$65.86 - $92.79 $10,537 - $14,846	-160 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$72.76 - $93.45 $11,641 - $14,952	160 New	160 $15,000
Q1 2019 May 03, 2019	SELL	$72.76 - $93.45 $11,641 - $14,952	-160 Closed	0 $0
Q3 2018 Oct 29, 2018	BUY	$87.52 - $122.67 $4,376 - $6,133	50 Added 45.45%	160 $14,000
Q2 2018 Aug 03, 2018	SELL	$88.31 - $107.8 $2,649 - $3,234	-30 Reduced 21.43%	110 $11,000
Q3 2017 Nov 01, 2017	BUY	$72.53 - $118.27 $10,154 - $16,557	140	140 $16,000

642

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $30.1B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Financial Architects, Inc, based on Form 13F filings with the SEC.

Stay updated on Financial Architects, Inc with notifications on news.